EdgarLookup

Vuzix Corp — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Vuzix Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-384.1%
Profit Margin
Net income ÷ revenue
-21.5%
Return on Assets
Net income ÷ assets
0.22x
Debt-to-Equity
Total liabilities ÷ equity
+93.2%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.24M Mar 12, 2026
FY2025 Sep 30, 2025 $1.16M Mar 12, 2026
FY2025 Jun 30, 2025 $1.30M Mar 12, 2026
FY2025 Mar 31, 2025 $1.58M Mar 12, 2026
FY2025 Dec 31, 2024 $1.27M Mar 12, 2026
FY2025 Sep 30, 2024 $1.39M Mar 12, 2026
FY2025 Jun 30, 2024 $1.09M Mar 12, 2026
FY2025 Mar 31, 2024 $2.00M Mar 12, 2026
FY2025 Dec 31, 2023 $1.07M Mar 12, 2026
FY2025 Sep 30, 2023 $2.18M Mar 12, 2026

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $1.6K Mar 16, 2018
FY2017 Sep 30, 2017 $1.4K Mar 16, 2018
FY2017 Jun 30, 2017 $1.3K Mar 16, 2018
FY2017 Mar 31, 2017 $1.2K Mar 16, 2018
FY2017 Dec 31, 2016 $620 Mar 16, 2018
FY2017 Sep 30, 2016 $583 Mar 16, 2018
FY2017 Jun 30, 2016 $561 Mar 16, 2018
FY2017 Mar 31, 2016 $364 Mar 16, 2018
FY2017 Dec 31, 2015 $2.75M Mar 16, 2018
FY2015 Dec 31, 2014 $3.03M Mar 30, 2016

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $375.0K Mar 12, 2026
FY2025 Sep 30, 2025 ($411.0K) Mar 12, 2026
FY2025 Jun 30, 2025 ($761.0K) Mar 12, 2026
FY2025 Mar 31, 2025 ($265.0K) Mar 12, 2026
FY2025 Dec 31, 2024 ($4.95M) Mar 12, 2026
FY2025 Sep 30, 2024 ($260.0K) Mar 12, 2026
FY2025 Jun 30, 2024 ($333.0K) Mar 12, 2026
FY2025 Mar 31, 2024 ($53.0K) Mar 12, 2026
FY2025 Dec 31, 2023 ($4.25M) Mar 12, 2026
FY2025 Sep 30, 2023 ($238.0K) Mar 12, 2026

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($8.62M) Mar 12, 2026
FY2025 Sep 30, 2025 ($7.35M) Mar 12, 2026
FY2025 Jun 30, 2025 ($7.67M) Mar 12, 2026
FY2025 Mar 31, 2025 ($8.64M) Mar 12, 2026
FY2025 Dec 31, 2024 ($13.66M) Mar 12, 2026
FY2025 Sep 30, 2024 ($9.22M) Mar 12, 2026
FY2025 Jun 30, 2024 ($40.61M) Mar 12, 2026
FY2025 Mar 31, 2024 ($10.05M) Mar 12, 2026
FY2025 Dec 31, 2023 ($19.88M) Mar 12, 2026
FY2025 Sep 30, 2023 ($10.98M) Mar 12, 2026

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($32.51M) Mar 12, 2026
FY2025 Dec 31, 2024 ($73.97M) Mar 12, 2026
FY2025 Dec 31, 2023 ($52.30M) Mar 12, 2026
FY2024 Dec 31, 2022 ($42.23M) Mar 13, 2025
FY2023 Dec 31, 2021 ($39.98M) Apr 15, 2024
FY2021 Sep 30, 2021 ($10.37M) Oct 25, 2022
FY2021 Jun 30, 2021 ($9.21M) Oct 25, 2022
FY2021 Mar 31, 2021 ($9.09M) Oct 25, 2022
FY2022 Dec 31, 2020 ($19.13M) Mar 1, 2023
FY2021 Dec 31, 2019 ($26.57M) Oct 25, 2022

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $12.63M Mar 12, 2026
FY2025 Dec 31, 2024 $9.63M Mar 12, 2026
FY2025 Dec 31, 2023 $12.34M Mar 12, 2026
FY2024 Dec 31, 2022 $12.68M Mar 13, 2025
FY2023 Dec 31, 2021 $11.67M Apr 15, 2024
FY2021 Sep 30, 2021 $3.40M Oct 25, 2022
FY2021 Jun 30, 2021 $2.72M Oct 25, 2022
FY2021 Mar 31, 2021 $2.21M Oct 25, 2022
FY2022 Dec 31, 2020 $7.57M Mar 1, 2023
FY2021 Dec 31, 2019 $8.90M Oct 25, 2022

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($18.79M) Mar 12, 2026
FY2025 Dec 31, 2024 ($23.74M) Mar 12, 2026
FY2025 Dec 31, 2023 ($26.28M) Mar 12, 2026
FY2024 Dec 31, 2022 ($24.52M) Mar 13, 2025
FY2023 Dec 31, 2021 ($26.98M) Apr 15, 2024
FY2021 Sep 30, 2021 ($18.91M) Oct 25, 2022
FY2021 Jun 30, 2021 ($13.11M) Oct 25, 2022
FY2021 Mar 31, 2021 ($5.92M) Oct 25, 2022
FY2022 Dec 31, 2020 ($13.96M) Mar 1, 2023
FY2021 Dec 31, 2019 ($22.36M) Oct 25, 2022

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.01M Mar 12, 2026
FY2025 Dec 31, 2024 $1.36M Mar 12, 2026
FY2025 Dec 31, 2023 $5.32M Mar 12, 2026
FY2024 Dec 31, 2022 $1.72M Mar 13, 2025
FY2023 Dec 31, 2021 $3.81M Apr 15, 2024
FY2022 Dec 31, 2020 $496.6K Mar 1, 2023
FY2021 Dec 31, 2019 $1.90M Oct 25, 2022
FY2020 Dec 31, 2018 $1.37M Mar 15, 2021
FY2019 Dec 31, 2017 $1.68M Mar 16, 2020
FY2018 Dec 31, 2016 $2.04M Mar 15, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $40.07M Mar 12, 2026
FY2025 Dec 31, 2024 $39.41M Mar 12, 2026
FY2024 Dec 31, 2023 $86.15M Mar 13, 2025
FY2023 Dec 31, 2022 $131.07M Apr 15, 2024
FY2022 Dec 31, 2021 $148.47M Mar 1, 2023
FY2021 Dec 31, 2020 $52.47M Oct 25, 2022
FY2020 Dec 31, 2019 $28.45M Mar 15, 2021
FY2019 Dec 31, 2018 $35.13M Mar 16, 2020
FY2018 Dec 31, 2017 $26.83M Mar 15, 2019
FY2017 Dec 31, 2016 $22.35M Mar 16, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $5.39M Mar 12, 2026
FY2025 Dec 31, 2024 $2.11M Mar 12, 2026
FY2024 Dec 31, 2023 $5.35M Mar 13, 2025
FY2023 Dec 31, 2022 $15.58M Apr 15, 2024
FY2022 Dec 31, 2021 $4.74M Mar 1, 2023
FY2021 Dec 31, 2020 $4.17M Oct 25, 2022
FY2020 Dec 31, 2019 $4.21M Mar 15, 2021
FY2019 Dec 31, 2018 $4.68M Mar 16, 2020
FY2018 Dec 31, 2017 $5.45M Mar 15, 2019
FY2017 Dec 31, 2016 $4.62M Mar 16, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $24.68M Mar 12, 2026
FY2025 Dec 31, 2024 $37.29M Mar 12, 2026
FY2025 Dec 31, 2023 $80.79M Mar 12, 2026
FY2025 Dec 31, 2022 $115.49M Mar 12, 2026
FY2024 Dec 31, 2021 $143.73M Mar 13, 2025
FY2023 Dec 31, 2020 $48.30M Apr 15, 2024
FY2022 Dec 31, 2019 $24.24M Mar 1, 2023
FY2021 Dec 31, 2018 $30.46M Oct 25, 2022
FY2020 Dec 31, 2017 $21.38M Mar 15, 2021
FY2019 Dec 31, 2016 $17.72M Mar 16, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2023 Dec 31, 2022 $1.60M Apr 15, 2024

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($399.86M) Mar 12, 2026
FY2025 Dec 31, 2024 ($367.52M) Mar 12, 2026
FY2024 Dec 31, 2023 ($293.98M) Mar 13, 2025
FY2023 Dec 31, 2022 ($243.84M) Apr 15, 2024
FY2022 Dec 31, 2021 ($203.07M) Mar 1, 2023
FY2021 Sep 30, 2021 ($191.58M) Oct 25, 2022
FY2021 Jun 30, 2021 ($181.09M) Oct 25, 2022
FY2021 Mar 31, 2021 ($171.85M) Oct 25, 2022
FY2021 Dec 31, 2020 ($162.69M) Oct 25, 2022
FY2020 Dec 31, 2019 ($144.74M) Mar 15, 2021

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $21.15M Mar 12, 2026
FY2025 Dec 31, 2024 $18.19M Mar 12, 2026
FY2024 Dec 31, 2023 $26.56M Mar 13, 2025
FY2023 Dec 31, 2022 $72.56M Apr 15, 2024
FY2022 Dec 31, 2021 $120.20M Mar 1, 2023
FY2021 Dec 31, 2020 $36.07M Oct 25, 2022
FY2020 Dec 31, 2019 $10.61M Mar 15, 2021
FY2020 Dec 31, 2018 $17.26M Mar 15, 2021
FY2020 Dec 31, 2017 $14.89M Mar 15, 2021
FY2019 Dec 31, 2016 $14.53M Mar 16, 2020

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $0 Mar 16, 2018
FY2017 Dec 31, 2016 $1.42M Mar 16, 2018
FY2016 Dec 31, 2015 $1.28M Mar 16, 2017
FY2015 Dec 31, 2014 $1.10M Mar 30, 2016
FY2014 Dec 31, 2013 $269.8K Mar 31, 2015
FY2013 Dec 31, 2012 $2.78M Apr 9, 2014
FY2012 Dec 31, 2011 $6.00M Mar 19, 2013

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 12, 2026
FY2025 Sep 30, 2025 0 Mar 12, 2026
FY2025 Jun 30, 2025 0 Mar 12, 2026
FY2025 Mar 31, 2025 0 Mar 12, 2026
FY2025 Dec 31, 2024 0 Mar 12, 2026
FY2025 Sep 30, 2024 0 Mar 12, 2026
FY2025 Jun 30, 2024 0 Mar 12, 2026
FY2025 Mar 31, 2024 0 Mar 12, 2026
FY2025 Dec 31, 2023 0 Mar 12, 2026
FY2025 Sep 30, 2023 0 Mar 12, 2026

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 12, 2026
FY2025 Sep 30, 2025 0 Mar 12, 2026
FY2025 Jun 30, 2025 0 Mar 12, 2026
FY2025 Mar 31, 2025 0 Mar 12, 2026
FY2025 Dec 31, 2024 0 Mar 12, 2026
FY2025 Sep 30, 2024 0 Mar 12, 2026
FY2025 Jun 30, 2024 0 Mar 12, 2026
FY2025 Mar 31, 2024 0 Mar 12, 2026
FY2025 Dec 31, 2023 0 Mar 12, 2026
FY2025 Sep 30, 2023 0 Mar 12, 2026

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 81.10M Mar 12, 2026
FY2025 Dec 31, 2024 75.97M Mar 12, 2026
FY2024 Dec 31, 2023 64.73M Mar 13, 2025
FY2023 Dec 31, 2022 63.32M Apr 15, 2024
FY2022 Dec 31, 2021 63.67M Mar 1, 2023
FY2021 Dec 31, 2020 45.65M Oct 25, 2022
FY2020 Dec 31, 2019 33.13M Mar 15, 2021
FY2019 Dec 31, 2018 27.59M Mar 16, 2020
FY2018 Dec 31, 2017 24.28M Mar 15, 2019
FY2017 Dec 31, 2016 19.57M Mar 16, 2018